Rituximab for secondary progressive multiple sclerosis: A case series

CNS Drugs

Volumn 25, Issue 7, 2011, Pages 607-613

  Rommer, Paulus S ^a   Patejdl, Robert ^a   Winkelmann, Alexander ^a   Benecke, Reiner ^a   Zettl, Uwe K ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Monoclonal antibodies; Multiple sclerosis; Rituximab

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MITOXANTRONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TREATMENT OUTCOME;

EID: 79959549561     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11589390-000000000-00000     Document Type: Article

References (18)

1. Stüve O, Kieseier BC, Hemmer B, et al Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol 2010 67 1307-15
2. Mix E, Meyer-Rienecker H, Hartung H, et al. Animal models of multiple sclerosis: potentials and limitations. Prog Neurobiol 2010; 92: 386-404
3. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779-87 (Pubitemid 39532369)
4. Kappos L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 2004; 10 Suppl. 1: S46-55 (Pubitemid 38807476)
5. Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: results of theMIMS trial. Neurology 2005; 65: 690-5 (Pubitemid 41285846)
6. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108 (Pubitemid 43157395)
7. Bielekova B, Howard T, Packer AN, et al. Effect of anti- CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66: 483-9
8. Waubant E. Spotlight on anti-CD20. Int MS J 2008; 15: 19-25
9. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-16
10. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-8
11. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88 (Pubitemid 351240747)
12. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008; 7: 538-47 (Pubitemid 351657494)
13. Hawker K, OConnor P, Freedman MS, et al., OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66 (4): 460-71
14. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of early clinical course. Brain 1989; 112: 1419-28 (Pubitemid 20024212)
15. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response inmultiple sclerosis. Mult Scler 1998; 4 (3): 111-7 (Pubitemid 28410034)
16. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-21
17. Goodin DS, Cohen BA, OConnor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology 2008; 71 (10): 766-73
18. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707-14